Stock DNA
Pharmaceuticals & Biotechnology
SEK 547 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.04
-50.50%
7.07
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
119.45%
0%
119.45%
6 Months
69.77%
0%
69.77%
1 Year
149.0%
0%
149.0%
2 Years
213.87%
0%
213.87%
3 Years
-10.22%
0%
-10.22%
4 Years
-5.44%
0%
-5.44%
5 Years
-66.29%
0%
-66.29%
Nanexa AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
33.13%
EBIT Growth (5y)
-181.97%
EBIT to Interest (avg)
-42.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.24
Tax Ratio
0.35%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.51
EV to EBIT
-7.96
EV to EBITDA
-11.74
EV to Capital Employed
4.17
EV to Sales
17.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-52.34%
ROE (Latest)
-34.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2.70
2.90
-6.90%
Operating Profit (PBDIT) excl Other Income
-9.20
-5.30
-73.58%
Interest
0.90
0.90
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.90
-9.00
34.44%
Operating Profit Margin (Excl OI)
-4,544.20%
-2,880.10%
-166.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -6.90% vs -35.56% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 34.44% vs 22.41% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
24.40
29.30
-16.72%
Operating Profit (PBDIT) excl Other Income
-20.80
-25.70
19.07%
Interest
0.50
0.50
Exceptional Items
0.00
-45.60
100.00%
Consolidate Net Profit
-24.90
-76.40
67.41%
Operating Profit Margin (Excl OI)
-1,082.80%
-1,056.00%
-2.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -16.72% vs 910.34% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 67.41% vs -30.38% in Dec 2023
About Nanexa AB 
Nanexa AB
Pharmaceuticals & Biotechnology
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Company Coordinates 
Company Details
Virdings Alle 32B , UPPSALA None : 754 50
Registrar Details






